Table 2.

Targeted therapy for BRAF-mutated NSCLC.

Trial	Treatment lines	Agents	ORR	PFS	OS
NCT01524978	≥2	Vemurafenib	42%	7.3	NA
EURAF Cohort	≥2	Vemurafenib, dabrafenib, or sorafenib	53%	5.0	10.8
AcSé	≥2	Vemurafenib	44.9%	5.2	10
NCT01336634	≥2	Dabrafenib	33%	5.5	NA
NCT02610361	≥2	BGB-283	20%	NA	NA
NCT01336634	≥2	Dabrafenib+Trametinib	63%	10.2	18.2
NCT01336634	1	Dabrafenib+Trametinib	64%	10.9	24.6
NCT02974725	≥2	LXH254+LTT462	66.7%	NA	NA